Open AccessConvalescent Plasma to Limit Coronavirus Associated Complications: A Proof of Concept Phase-2 Clinical Study at a designated COVID-19 hospital in Mumbai city
Author(s) -
Behram Pardiwalla,
Anuja Yadav,
Ashima Bhatia,
Kedar Toraskar,
Vijay Sharma,
Manishkumar Shah,
Ranjeet Gutte,
Dhananjay D. Kumbhar,
Dhaval Gohel,
Preeti Narayan,
Honey Savla,
N.P.Chotai C.D.Nagda.,
A. Bopardikar
Publication year - 2021
Publication title -
journal of current medical research and opinion
Language(s) - English
Resource type - Journals
eISSN - 2589-8779
pISSN - 2589-8760
DOI - 10.15520/jcmro.v4i05.419
Subject(s) - medicine , ards , fraction of inspired oxygen , covid-19 , convalescence , convalescent plasma , confidence interval , oxygen saturation , mechanical ventilation , emergency medicine , anesthesia , lung , disease , infectious disease (medical specialty) , chemistry , organic chemistry , oxygen
Objective: With few treatment options available to manage coronavirus disease 2019 (COVID-19), health systems devised strategies to manage covid-19 using repurposed drugs and revisiting older strategies, such as convalescent plasma. This study was planned to evaluate safety and efficacy of Anti-SARS-CoV-2 convalescent plasma in hospitalized subjects with COVID-19.
Method: An open label, single centre, two arm, prospective, randomised, controlled exploratory phase 2 study was conducted at a covid-19 designated center. 20 subjects (≥18 years) were admitted to hospital (screened 15 June to 27 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen (PaO2/FiO2) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 10 subjects were assigned to convalescent plasma with standard treatment (test arm) and 10 subjects to standard treatment only (control arm). Subjects in the test arm received either single or two doses of convalescent plasma 24 hours apart based on their clinical condition as per investigator’s discretion.
Results: Subjects in test arm showed earlier resolution of symptoms of fever, shortness of breath and cough and the mean duration for RT-PCR test turning negative was better in the test arm. One subject in the control arm progressed to severe ARDS, while none in test arm progressed to severe ARDS. There was no difference in the use of respiratory support (invasive and non-invasive ventilation) between the 2 arms. There was no mortality observed in the study and no serious adverse reaction observed with the transfusion of convalescent plasma in the study.
Conclusion: This was an exploratory proof of concept study to explore the effectiveness of convalescent plasma in COVID-19 subjects and sample size was not large enough to detect a statistically significant difference however subjects in test arm of this study showed better outcomes in few of the efficacy parameters as compared to subjects in control arm. The use of convalescent plasma transfusion was also observed to be safe.